公开(公告)号：US20230414516A1

公开(公告)日：2023-12-28

申请号：US18036676

申请日：2021-11-15

Applicant: BioNTech SE

Inventor： Bakul Subodh Bhatnagar ,  Ramin Darvari ,  Sumit Luthra ,  Serguei A. Tchessalov ,  Steffen Panzner ,  Christian Reinsch ,  Kaushik Thanki ,  Sukrut Somani

IPC: A61K9/19 ,  A61K9/16 ,  A61K9/51 ,  A61K31/7105

CPC classification number: A61K9/19 ,  A61K9/1694 ,  A61K9/1623 ,  A61K9/5123 ,  A61K31/7105

Abstract: This invention relates to enhanced stabilization and improved lyophilization methods of pharmaceutical substances.

公开(公告)号：US20230390485A1

公开(公告)日：2023-12-07

申请号：US18180073

申请日：2023-03-07

Applicant: Genentech ,  BioNTech SE

Inventor： Robert Daniel OVADIA ,  Christopher Andrew Petry ,  Fredric John Lim ,  Heinrich Haas ,  Sebastian Hoerner ,  Ferdia Bates ,  Tobias Kind ,  Peer Andre Berger

IPC: A61M5/142

CPC classification number: A61M5/14228 ,  A61M2205/07

Abstract: Provided herein are methods and systems for use with peristaltic pumps. More particularly, provided herein are peristaltic pump systems that include a dampener for reducing the pulsations of the flowrate from the peristaltic pump system to produce, mix, transfer and/or manufacture pharmaceutical compositions and formulations, including pharmaceutical compositions and formulations comprising lipids and RNA.

公开(公告)号：US20230330198A1

公开(公告)日：2023-10-19

申请号：US18333273

申请日：2023-06-12

Applicant: BioNTech SE ,  TRON - Translationale Onkologie an der Universitatsmedizin der Johannes Gutenberg-Universitat Mainz

Inventor： Ugur Sahin ,  Sebastian Kreiter ,  Christina Krienke ,  Jutta Petschenka ,  Lena Mareen Kranz ,  Mustafa Diken

IPC: A61K39/00 ,  A61P37/06 ,  C12N15/11 ,  C12N15/117

CPC classification number: A61K39/0008 ,  A61P37/06 ,  C12N15/11 ,  C12N15/117 ,  A61K2039/53 ,  A61K2039/55555 ,  C12N2310/335

Abstract: The present invention relates to non-immunogenic RNA. This RNA forms the basis for the development of therapeutic agents for inducing tolerance towards an autoantigen and thus, for the treatment of autoimmune diseases.

公开(公告)号：US20230295335A1

公开(公告)日：2023-09-21

申请号：US18184120

申请日：2023-03-15

Applicant: Genmab A/S ,  BioNTech SE

Inventor： Andreea IOAN ,  Esther Cornelia Wilhelmina BREIJ ,  Lars GUELEN ,  David P.E. SATIJN ,  Ugur SAHIN ,  Alexander MUIK ,  Kristina SCHÖDEL ,  Sina FELLERMEIER-KOPF ,  Bart-Jan DE KREUK ,  Richard HIBBERT ,  Janine SCHUURMAN ,  Aran Frank LABRIJN

IPC: C07K16/30 ,  C07K16/28

CPC classification number: C07K16/30 ,  C07K16/2878 ,  C07K2317/31 ,  C07K2317/92

Abstract: The present invention provides a binding agent that binds to EpCAM and to CD137 which is useful to treat or prevent a tumor or cancer, or to prevent progression of a tumor or cancer.

公开(公告)号：US20230272406A1

公开(公告)日：2023-08-31

申请号：US17936377

申请日：2022-09-28

Applicant: BioNTech SE ,  TRON-Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz gG

Inventor： Alexandra Orlandini Von Niessen ,  Stephanie Fesser ,  Britta Vallazza ,  Tim Beissert ,  Andreas Kuhn ,  Ugur Sahin ,  Marco Alexander Poleganov

IPC: C12N15/67 ,  A47B3/00 ,  A47B13/02 ,  A47B33/00 ,  A47B43/00 ,  A47B77/02 ,  A47B77/06 ,  A47B77/08 ,  A47B77/16 ,  A47B77/18 ,  A47B95/00 ,  A47C4/00 ,  A47C4/08 ,  A47C7/00 ,  A47K3/28 ,  B60B33/00 ,  E04H1/12 ,  F16C11/04 ,  C12N5/0735 ,  C12N15/113 ,  C12N15/90

CPC classification number: C12N15/67 ,  A47B3/002 ,  A47B13/02 ,  A47B33/00 ,  A47B43/00 ,  A47B77/022 ,  A47B77/06 ,  A47B77/08 ,  A47B77/16 ,  A47B77/18 ,  A47B95/00 ,  A47B95/008 ,  A47C4/00 ,  A47C4/08 ,  A47C7/002 ,  A47C7/006 ,  A47K3/284 ,  B60B33/00 ,  E04H1/1266 ,  F16C11/04 ,  C12N5/0606 ,  C12N15/113 ,  C12N15/90 ,  A47B2003/006 ,  A47B2200/0018 ,  C12N2310/113

Abstract: The present invention relates to stabilization of RNA, in particular mRNA, and an increase in mRNA translation. The present invention particularly relates to a modification of RNA, in particular in vitro-transcribed RNA, resulting in increased transcript stability and/or translation efficiency. According to the invention, it was demonstrated that certain sequences in the 3′-untranslated region (UTR) of an RNA molecule improve stability and translation efficiency.

公开(公告)号：US20220381748A1

公开(公告)日：2022-12-01

申请号：US17627066

申请日：2020-07-17

Applicant: BioNTech SE

Inventor： Heinrich HAAS ,  Tijana BACIC ,  Jens SCHUMACHER

IPC: G01N30/00 ,  G01N15/02 ,  G01N30/74

Abstract: The present disclosure relates generally to the field of analyzing a nucleic acid, such as RNA, in particular to the determination of at least one parameter of a sample composition comprising a nucleic acid, especially RNA, and optionally particles.

公开(公告)号：US11440966B2

公开(公告)日：2022-09-13

申请号：US17345628

申请日：2021-06-11

Applicant: GENMAB A/S ,  BioNTech SE

Inventor： Isil Altintas ,  David Satijn ,  Rik Rademaker ,  Paul Parren ,  Friederike Gieseke ,  Ugur Sahin

IPC: C07K16/28 ,  A61K39/395 ,  G01N33/569

Abstract: Multispecific antibodies binding to human CD40 and human CD137, methods for preparing such multispecific antibodies, and methods of using such multispecific antibodies for therapeutic or other purposes.

公开(公告)号：US20220257631A1

公开(公告)日：2022-08-18

申请号：US17595587

申请日：2020-05-20

Applicant: BIONTECH SE ,  TRON - TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITÄTSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITÄT MAINZ

Inventor： Ugur SAHIN ,  David WEBER ,  Carina WALTER ,  Diana BAREA ROLDAN ,  Ruprecht KUNER ,  Meike WAGNER ,  Martin SUCHAN ,  Stefania GANGI MAURICI ,  Stefanie HUBICH-RAU ,  René BECKER

IPC: A61K31/7088 ,  A61P35/00 ,  A61K9/00

Abstract: Disclosed herein are compositions, uses, and methods for treatment of ovarian cancers. In one aspect, provided herein is a composition or medical preparation comprising at least one RNA, wherein the at least one RNA encodes the following amino acid sequences: (i) an amino acid sequence comprising claudin 6 (CLDN6), an immunogenic variant thereof, or an immunogenic fragment of the CLDN6 or the immunogenic variant thereof; (ii) an amino acid sequence comprising p53, an immunogenic variant thereof, or an immunogenic fragment of the p53 or the immunogenic variant thereof; and (iii) an amino acid sequence comprising Preferentially Expressed Antigen In Melanoma (PRAME), an immunogenic variant thereof, or an immunogenic fragment of the PRAME or the immunogenic variant thereof.

公开(公告)号：US20220144822A1

公开(公告)日：2022-05-12

申请号：US17432017

申请日：2020-03-06

Applicant: BioNTech SE

Inventor： Christophe HENRY

IPC: C07D471/04 ,  C07D215/46

Abstract: The present invention relates to a process for synthesizing N-(4-(4-amino-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl)butyl)-N-(tetrahydro-2H-pyran-4-yl)acetamide, an imidazoquinoline derivative useful as toll-like receptor agonist, in particular as an agonist of TLR7, which promotes induction of certain cytokines. Furthermore, the present invention also provides intermediates useful in the synthesis of N-(4-(4-amino-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl)butyl)-N-(tetrahydro-2H-pyran-4-yl)acetamide.

公开(公告)号：US20220143144A1

公开(公告)日：2022-05-12

申请号：US17442568

申请日：2020-04-02

Applicant: BIONTECH SE ,  TRON-Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz

Inventor： Ugur SAHIN ,  Mathias VORMEHR ,  Lena KRANZ ,  Sina FELLERMEIER-KOPF ,  Alexander MUIK ,  Daniel REIDENBACH ,  Mustafa DIKEN ,  Sebastian KREITER

IPC: A61K38/20 ,  A61K38/21 ,  A61P37/04 ,  A61P35/00

Abstract: The present disclosure relates to methods and agents for enhancing the effect of immune effector cells, in particular immune effector cells that respond to interleukin-2 (IL2), for example effector T cells such as CD8+ T cells. Specifically, the present disclosure relates to methods comprising administering to a subject a polypeptide comprising IL2 or a functional variant thereof or a polynucleotide encoding a polypeptide comprising IL2 or a functional variant thereof and a polypeptide comprising type I interferon (IFN) or a functional variant thereof or a polynucleotide encoding a polypeptide comprising type I interferon or a functional variant thereof.